Cell based Library Screening Service

Introduction Our Services Workflow Platform Cases Advantages FAQ Resources

Cell-based Screening: Real-Time Interaction Analysis with Living Cells

Binder discovery against native receptors, membrane proteins, or whole-cell phenotypes.

At Creative Biolabs, we believe meaningful discovery begins with relevance. Our cell-based phage display library screening service is built to reflect complex biological systems in a controlled, functional environment. By using living cells as the selection platform, this approach offers unparalleled insight into how ligands or peptides behave in a natural context—whether you're targeting membrane proteins, receptors, or studying internalization processes. Creative Biolabs' experienced team brings decades of cumulative expertise to ensure your screening is precise, scalable, and biologically meaningful.

What We Offer: Tailored Cell-Centric Screening

Our cell-based phage display screening service is designed to mimic the real biological complexity that traditional in vitro platforms often overlook. Creative Biolabs' scientists tailor every aspect of the screening to your target and research objective.

Custom or Ready-to-Use Libraries

Access to immune, synthetic, and pre-made phage libraries for rapid and versatile binder discovery.

Flexible Cell Models

Use of adherent or suspension cell lines, including cancer, immune, neural, and stem cell lines; primary cells and patient-derived cells are also supported.

Targeting of Diverse Epitopes

Screening can be performed on surface-expressed proteins, internal targets (via permeabilization), or context-dependent antigens.

Advanced Counter-Selection

Use of genetically similar or isogenic cell lines to subtract background binders and enrich for truly specific interactions.

Internalization and Trafficking Analysis

Identify ligands that not only bind but also internalize or localize to specific cellular compartments.

Optional Post-screening Assays

Clone-level ELISA, confocal imaging, or flow cytometry to validate specificity and functionality.

Creative Biolabs provides end-to-end support, from project design to hit validation, ensuring your results are both biologically meaningful and technically robust.

Our Process: From Cell Surface to Sequence

Our carefully designed stepwise workflow includes:

1. Cell Culture & Preparation

Defined growth conditions ensure optimal target expression and viability.
Cell lines are cultured under standardized and serum-controlled conditions.
Surface markers and target expression levels are verified before screening.

2. Blocking & Pre-adsorption

Pre-clearing against irrelevant cells minimizes non-specific binding.
Phage libraries are incubated with control or irrelevant cells to remove background clones.
Reduces off-target binding and enhances specificity in downstream panning.

3. Phage Incubation

Library exposure at 4°C (surface binding) or 37°C (internalization).
Controlled temperature and time conditions allow natural interaction kinetics.
Facilitates selection of binders for either surface or internalized antigens.

4. Washing & Elution

Optimized washing and elution steps preserve infectivity while enriching true binders.
Sequential washes with increasing stringency remove weak or non-specific binders.
Elution is performed using mild acid, pH shift, or competition to recover strong binders.

5. Amplification & Enrichment

Amplified phage pools undergo multiple panning rounds for specificity.
Amplification in E. coli ensures phage viability and maintains library diversity.
Typically 2–4 rounds are performed to enrich for high-affinity, target-specific clones.

6. Clone Characterization

Enriched clones are evaluated by ELISA, sequencing, or binding assays.
Individual phage clones are screened to confirm specific binding activity.
DNA sequencing identifies unique candidates for further validation.

7. Functional Validation (Optional)

Confocal microscopy or flow cytometry confirms internalization or binding activity.
Binding specificity and internalization behavior are visualized at the cellular level.
Validated binders can advance to therapeutic, diagnostic, or functional studies.

What You'll Receive

Upon completion, Creative Biolabs will deliver:

Summary of cell lines and conditions used
Enrichment statistics across panning rounds
ELISA or binding assay data for top clones
NGS or Sanger sequencing data of enriched clones
Optional clone expression and validation data
Full experimental report with recommendations

We also store enriched libraries for 3 months for any requested follow-up services.

Spotlight on Platforms: Expanding Beyond the Dish

Creative Biolabs' platform is designed to be compatible with advanced downstream assays. Once lead binders are identified, we can help transition your candidate into in vivo studies, including:

Animal-based validation
Imaging-tagged binder evaluation
Biodistribution analysis

This modularity ensures you don't just identify a binder—you identify one that works where it matters most.
Our cell-based workflow complements several other powerful phage display approaches. Based on your application, Creative Biolabs also offers:

Fig.1 Solid-Phase. (Creative Biolabs AI)

Solid-Phase Screening – for purified or immobilized target proteins

Fig.2 Solution-Sorting Strategy. (Creative Biolabs AI)

Solution-Sorting Strategy – unbiased selection in a free-form environment

Fig.3 Protease Substrate Screening. (Creative Biolabs AI)

Protease Substrate-based Screening – mapping cleavage signatures with precision

Fig.4 In Vivo Phage Display. (Creative Biolabs AI)

In Vivo Phage Display Screening – for true physiological targeting

Fig.5 Ex Vivo Display Screening. (Creative Biolabs AI)

Ex Vivo Display Screening – ideal for tissue-specific discovery

Each platform serves a unique purpose. Creative Biolabs can help you mix and match approaches to build a screening cascade that maximizes discovery potential.

Case Highlights: Successful Outcomes from Our Screening

Case 1: Discovery of High-Affinity Internalizing Antibodies

Objective: Isolate human scFv antibodies that specifically bind and internalize into a custom target cell line.

Challenge	Our Solution	Key Outcomes
Identify antibodies that not only bind but are actively internalized by target cells. Ensure high specificity with no cross-reactivity to control cell lines. Rapidly deliver a diverse set of candidate sequences.	Library: Screened our proprietary premade Human scFv Phage Display Library (>10¹⁰ diversity). Strategy: Internalization Screening. Employed multiple rounds of cell-based panning, incorporating a low-pH acid wash step to specifically elute and enrich for internalized phage particles. Validation: Performed cell-based ELISA and FACS analysis to confirm both high-affinity binding and specificity.	Enrichment of target-specific phage pool after 4 rounds. FACS validation confirmed selective binding and internalization capabilities of the enriched pool. Top 10 unique antibody sequences identified via NGS, with diverse CDRs. Sequences delivered to the client for downstream development.

Representative Data:

Phage output titers increased over four rounds of panning, indicating successful enrichment of target-specific binders.

Positive enrichment validated by phage-based FACS.

NGS of the enriched pool revealed the relative frequency of the top 10 unique scFv clonotypes.

Case 2: Targeting a Complex Multi-Pass Transmembrane Protein

Objective: Discover antibodies against complex multi-pass transmembrane protein that is notoriously difficult to express and purify while maintaining its native structure.

Challenge	Our Solution	Key Outcomes
The target protein's complex structure is lost upon purification. Required antibodies that recognize the native, conformationally correct epitopes on the cell surface.	Target Presentation: Developed a stable HEK293 cell line overexpressing the target. Strategy: Conformationally Sensitive Screening. Utilized whole-cell panning to present the target in its native membrane environment, ensuring selection against physiologically relevant epitopes. Validation: Monoclonal phage ELISA was performed to confirm the binding of individual clones.	Successfully bypassed the need for protein purification. Achieved significant signal enrichment in panning outputs, confirming the presence of specific binders. NGS analysis revealed 10 dominant clonal families of antibodies. Lead candidates were evaluated in functional cell-based assays.

Representative Data:

ELISA and FACS results for individual phage clones, showing strong binding signals to the target-overexpressing cells (Target+) compared to control cells (Target-).

Frequency distribution of the top 10 antibody sequences identified by NGS post-panning. The high abundance of a few dominant clones indicates successful and specific selection.

Why Choose Creative Biolabs: Our Competitive Edge

Biological Relevance

Native-like systems that reveal functional binding

Customization

Library type, selection pressure, cell model—your goals drive our design

Scalability

From pilot screening to high-throughput selection

Fast Turnaround

Most projects are completed within 8-10 weeks

Transparent Communication

Clear timelines, regular updates, and collaborative troubleshooting

For more information or to discuss your specific project needs, please contact Creative Biolabs' scientific team. We are committed to advancing your research through innovative and reliable screening solutions.

FAQs: Getting Started with Cell-Based Screening

Q: What cell types do you support?
A: We can work with most mammalian cell lines, primary cells, and custom-engineered models. If you have unique requirements, our team will help assess feasibility.
Q: Do I need to supply the cell line?
A: You're welcome to provide your own cells, but we also maintain a validated panel of common cell lines for convenience.
Q: What kind of library can be used?
A: We support peptide libraries, scFv libraries, and other antibody formats. Library quality will be assessed before use.
Q: Can you distinguish between similar cell types?
A: Yes. We use differential selection (positive/negative sorting) strategies to discriminate binders between closely related cell populations.
Q: Is internalization screening possible?
A: Absolutely. We design temperature and time conditions to select for internalizing binders, ideal for therapeutic delivery vectors.
Q: What if my target is low abundance?
A: We can optimize incubation times, library size, and amplification steps to boost sensitivity.
Q: Can I get binding data in addition to sequences?
A: Yes, binding assays via ELISA, FACS, or microscopy can be included depending on your selection type and application.